2014 Archived Content

Cambridge Healthtech Institute’s Second Annual

Predictive Preclinical Models in Oncology

Delivering Reproducible and Predictive Research Resultss

February 10-12, 2014 | Moscone North Convention Center | San Francisco, CA


Day 1 | Day 2 | Day 3 | Download Brochure 

Wednesday, February 12

7:00 am Breakfast Presentation (Sponsorship Opportunity Available) or Morning Coffee

8:00 Plenary Keynote Session (Click Here For More Details) 

9:45 Refreshment Break and Poster Competition Winner Announced in the Exhibit Hall


10:35 Chairperson’s Remarks

Tom Metcalfe, BSc, MBA, Managing Director, Oncotest

10:40 Targeting Cancer with BiTE™ Molecules

Holger Wesche, Ph.D., Scientific Director, Oncology, Amgen, Inc.

The recent clinical success in harnessing the immune system to fight cancer has demonstrated the potential of this approach. Here we will give an overview of the BiTE (Bi-specific T-cell Engager) technology, which drives directed T cell mediated tumor cell killing.

11:10 Molecular Analysis of Mouse Syngeneic Tumor Models as a Translational Tool in Understanding Anti-PD1 Immunotherapy

Terrill K. McClanahan, Ph.D., Senior Principal Scientist, Molecular Discovery, Biology & Pharmacology Merck Research Labs, Biologics

The utility of mouse syngeneic tumor models to develop immunomodulatory agents for oncology will be discussed. We have studied anti-tumor efficacy, pharmacology and pharmacodynamics of a surrogate anti-mouse PD-1 antibody for mechanistic biomarker discovery and translation to human clinical studies.

11:40 Missing The Targets: Why In Vivo Models Are Not Up To The Job

Bent Jakobsen, Ph.D., CSO, Immunocore

Since immunotherapies interact specifically with human target molecules, preclinical assessment using animal models requires careful consideration. We describe an alternative approach based on in vitro molecular and cellular testing, and apply this strategy to a novel TCR-based therapeutic possessing dual specificity for human targets.

12:10 pm Session Break

12:20 Luncheon Presentation (Sponsorship Opportunity Available) or Lunch on Your Own

1:00 Refreshment Break in the Exhibit Hall and Last Chance for Poster Viewing


1:40 Chairperson’s Remarks
Vivienne Watson, Ph.D., Senior Scientist, Amgen  

1:45 Modeling Tumor Heterogeneity: Accounting for CSCs and the Immune System

Elaine Hurt, Ph.D., Scientist II, MedImmune

At MedImmune we are developing in vivo models encompassing several important attributes of cancer, including recapitulating the heterogeneity of tumors by using patient-derived xenografts, understanding the contribution of cancer stem cells and circulating tumor cells, as well as modeling the role of the immune system. Through the development and use of these complex biological systems we strive to develop therapeutics that have long-lasting benefit to our patients.

2:15 Integration of Cell Line Sensitivity and Genomic Profiling Data for Patient Stratification

Vivienne Watson, Ph.D., Senior Scientist, Amgen

We have performed a functional screen using an siRNA library representing more than 14,000 genes on a set of cancer cell lines that contain genetic lesions known to be representative of a subset of lung cancer primary tumors. An association analysis to look for genomic markers that correlate with sensitivity, and that would identify a potential target patient population, was carried out. The data will be discussed.

2:45 Development of a Clinically Relevant Model of Metastatic Colorectal Cancer

Kevin G. Leong, Ph.D., Scientist, Discovery Oncology, Genentech, Inc.

Despite the availability of xenograft, chemical-induced, and genetically-engineered mouse models of colorectal cancer, none of these models reproducibly metastasize to target organs relevant to the human disease. We have developed a novel mouse model of metastatic colorectal cancer that exhibits robust metastasis to clinically relevant target organs, and have utilized this model to investigate routes of metastatic dissemination.

3:15 Sponsored Presentations (Opportunities Available) 

3:45 Refreshment Break

4:00 Chairperson’s Remarks


4:05 Impact of Aging and Body Fat on Outcome in Preclinical Cancer Models

William J. Murphy, Ph.D., Professor and Acting Chair, Department of Dermatology; Professor, Department of Internal Medicine, Division of Hematology/Oncology, University of California, Davis School of Medicine

We have found that acute toxicities can be observed when using older but not young mice and this is dependent on body fat and a heightened inflammatory state following immunotherapies.

4:35 Increasing the Breadth and the Bandwidth of Preclinical Assessment in Biologically Engineered Murine Cancer Models

Serguei Kozlov, Ph.D., Principal Scientist, Center for Advanced Preclinical Research, SAIC-Frederick, Inc.

Genetic de novo cancer models have been earning rising attention as capable of providing experimental platforms featuring autochthonous carcinogenesis for informative decisions at preclinical stages. These models however are laborious, costly and require versatile expertise to manage workflows involving mouse lines engineered to mimic cancer. Strategies have been developed to “retool” conventional GEMs into more tractable alternatives to broaden and accelerate their translational applications.

5:05 Panel Discussion: Quality of Murine Models: What This Definition IncludesPanelists: Speakers of the Day 

5:35 Close of Conference Program

Day 1 | Day 2 | Day 3 | Download Brochure 

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag  

Premier Sponsors

Beckman Coulter Life Sciences 

Boston Healthcare



Charles River no tagline


Cofactor Genonics


Menarini Silicon Biosystems






View All Sponsors